Compare NMIH & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMIH | HTFL |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2013 | 2025 |
| Metric | NMIH | HTFL |
|---|---|---|
| Price | $37.51 | $27.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $41.20 | $39.50 |
| AVG Volume (30 Days) | 408.3K | ★ 666.3K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $692,208,000.00 | $161,881,000.00 |
| Revenue This Year | N/A | $40.42 |
| Revenue Next Year | $4.79 | $22.27 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | 8.86 | ★ 85.70 |
| 52 Week Low | $31.90 | $25.75 |
| 52 Week High | $43.20 | $41.22 |
| Indicator | NMIH | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | N/A |
| Support Level | $37.91 | N/A |
| Resistance Level | $38.90 | N/A |
| Average True Range (ATR) | 0.70 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 41.45 | 0.00 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.